中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2014年
4期
325-327
,共3页
应志涛%王雪鹃%宋玉琴%郑文%王小沛%谢彦%林宁晶%涂梅峰%平凌燕
應誌濤%王雪鵑%宋玉琴%鄭文%王小沛%謝彥%林寧晶%塗梅峰%平凌燕
응지도%왕설견%송옥금%정문%왕소패%사언%림저정%도매봉%평릉연
氟脱氧葡萄糖F18%霍奇金病%预后%存活率分析
氟脫氧葡萄糖F18%霍奇金病%預後%存活率分析
불탈양포도당F18%곽기금병%예후%존활솔분석
Fluorodeoxyglucose F18%Hodgkin disease%Prognosis%Survival analysis
目的 探讨PET-CT在霍奇金淋巴瘤(HL)患者中的预后价值.方法 回顾性分析50例初治HL患者资料.所有患者在一线治疗前、治疗中期或者治疗后接受氟脱氧葡萄糖F18(18F-FDG)PET-CT检查,采用SPSS 13.0软件对患者生存进行分析.结果 50例患者一线接受ABVD(多柔比星+博来霉素+长春新碱+氮烯咪胺)或BEACOPP(博来霉素+依托泊苷+多柔比星+环磷酰胺+长春新碱+甲基苄肼+泼尼松)方案化疗.中位随访时间29.4(12.2～52.4)个月.接受中期、治疗后PET-CT检查的患者分别为35、46例.中期PET-CT阴性、阳性患者分别为25、10例,3年无进展生存(PFS)率分别为100％、70％,差异有统计学意义(P=0.004).治疗后PET-CT阴性、阳性患者分别为36、10例,3年PFS率分别为100％、60％,差异有统计学意义(P＜0.01).结论 治疗中期和治疗后PET-CT结果与HL患者PFS存在相关性,与总生存率的关系因随访时间过短不能确定.
目的 探討PET-CT在霍奇金淋巴瘤(HL)患者中的預後價值.方法 迴顧性分析50例初治HL患者資料.所有患者在一線治療前、治療中期或者治療後接受氟脫氧葡萄糖F18(18F-FDG)PET-CT檢查,採用SPSS 13.0軟件對患者生存進行分析.結果 50例患者一線接受ABVD(多柔比星+博來黴素+長春新堿+氮烯咪胺)或BEACOPP(博來黴素+依託泊苷+多柔比星+環燐酰胺+長春新堿+甲基芐肼+潑尼鬆)方案化療.中位隨訪時間29.4(12.2～52.4)箇月.接受中期、治療後PET-CT檢查的患者分彆為35、46例.中期PET-CT陰性、暘性患者分彆為25、10例,3年無進展生存(PFS)率分彆為100％、70％,差異有統計學意義(P=0.004).治療後PET-CT陰性、暘性患者分彆為36、10例,3年PFS率分彆為100％、60％,差異有統計學意義(P＜0.01).結論 治療中期和治療後PET-CT結果與HL患者PFS存在相關性,與總生存率的關繫因隨訪時間過短不能確定.
목적 탐토PET-CT재곽기금림파류(HL)환자중적예후개치.방법 회고성분석50례초치HL환자자료.소유환자재일선치료전、치료중기혹자치료후접수불탈양포도당F18(18F-FDG)PET-CT검사,채용SPSS 13.0연건대환자생존진행분석.결과 50례환자일선접수ABVD(다유비성+박래매소+장춘신감+담희미알)혹BEACOPP(박래매소+의탁박감+다유비성+배린선알+장춘신감+갑기변정+발니송)방안화료.중위수방시간29.4(12.2～52.4)개월.접수중기、치료후PET-CT검사적환자분별위35、46례.중기PET-CT음성、양성환자분별위25、10례,3년무진전생존(PFS)솔분별위100％、70％,차이유통계학의의(P=0.004).치료후PET-CT음성、양성환자분별위36、10례,3년PFS솔분별위100％、60％,차이유통계학의의(P＜0.01).결론 치료중기화치료후PET-CT결과여HL환자PFS존재상관성,여총생존솔적관계인수방시간과단불능학정.
Objective To determine the predictive value of interim and end-of-treatment 18F-FDG PET-CT after first-line treatment in patients with Hodgkin lymphoma (HL).Methods The clinical data of 50 newly diagnosed HL patients were retrospectively analyzed.Baseline,interim and end-of-treatment PET-CT were performed,and then imaging results were analyzed for the survival of patients via software SPSS 13.0.Results Fifty patients received first-line treatment with ABVD (doxorubicin + bleomycin + vincristine + dacarbazine) or BEACOPP (bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine+ prednisone) regimen.Interim PET-CT of 35 patients were performed after 2-4 cycles of treatment,46 patients received PET-CT scans at the end of treatment.After a median follow-up of 29.4 months (12.2-52.4 months),the 3-year progression-free survival (PFS) rates were 100％ and 70％ for the interim PET-CT negative (n=25) and positive (n=10) patients,respectively (P=0.004).The 3-year PFS rates were 100％ and 60％ for the post-treatment PET-CT negative (n=36) and positive (n=10) patients,respectively (P＜0.01).Conclusion Interim and end-of-treatment PET-CT were correlated with 3-year PFS rates for HL patients.They may play an important role in predicting the outcome of HL.The relationship with OS can not be determined because of the short follow-up time.
